Expert Interview
Investigating Moderna's Human Cytomegalovirus mRNA-1647 Vaccine Candidate and the potential in CMV
Ticker(s): MRNAInstitution: Private Practice
- Board certified in Internal Medicine and Infectious Disease
- Familiar with CMV infection and health complications
- Private practice serves patients across five nearby acute care hospitals
Roughly how many patients do you see yearly for CMV?
Added By: c_adminOn a scale from 1-10 (10 being extremely excited) where would you rate your level of excitement for mrna-1647?
Added By: c_adminWhat kind of vaccine efficacy would be clinically meaningful? Would stat significance be sufficient?
What are your thoughts on the vaccine’s existing tolerability profile?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
